Jan M. Lundberg, Ph.D.

Jan M. Lundberg, Ph.D.

Dr. Jan Lundberg has over two decades of executive leadership experience in the pharmaceutical sector and held c-suite positions with leading companies, including Eli Lilly and AstraZeneca.  Dr. Lundberg most recently held the position of executive vice president, science and technology, and president, Lilly Research Laboratories at Eli Lilly.  During his career he has led the development of more than 200 candidate drugs, with 25 approved products across multiple therapeutic areas.  Before joining AstraZeneca, Dr. Lundberg held the position of Professor of Pharmacology at the Karolinska Institute in Solna, Sweden.  In addition to his significant industry experience, Dr. Lundberg is the co-founder of Aerocrine AB and currently serves on the boards of directors of Anocca, Ardelyx, Betagenon, Image Analysis Group, Metabolon and TB Alliance.

Dr. Lundberg completed 4 years of medical school at the University of Gothenburg and his doctorate at the Karolinska Institute. 


Anil K. Singhal, Ph.D.

Anil K. Singhal, Ph.D.

Dr. Anil Singhal has over 3 decades in academic and senior executive roles with large pharmaceutical companies, startups and leading biotech companies.  Dr. Singhal currently serves as the President & CEO of Adicet Bio, a pre-clinical stage biotechnology company engaged in the design and development of cutting-edge allogeneic immunotherapies for cancer and other diseases.  Before joining Adicet Bio, he served as Executive in Residence at Canaan Partners and CSO at OncoResponse Inc.  Dr. Singhal served as Vice President of Early Oncology Development at AbbVie and Head of AbbVie- Redwood City site.  As a member of the R&D leadership team, he helped to build an impressive portfolio and key translational science capabilities in oncology, immunology and other diseases.  Dr. Singhal has held senior roles in the US, Japanese and German biopharma/ biotechnology industry for over 30 years.  Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at University of Washington.

Dr. Singhal holds a PhD from Wakesman Institute of Rutgers University and an Executive MBA from University of Washington.


Gerald T. Nepom, Ph.D., M.D.

Gerald T. Nepom, Ph.D., M.D.

Dr. Gerald (Jerry) Nepom has served in academic and executive leadership roles for over 30 years with a focus on immunology, autoimmunity, and immunotherapy research.   Dr. Nepom is currently the Director of the NIAID-sponsored Immune Tolerance Network (ITN), designing and leading clinical trials in transplantation, allergy, and autoimmune disease. He is the founder and former Director of the Benaroya Research Institute at Virginia Mason (BRI), and previously served as faculty at the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine.   Dr. Nepom serves on numerous editorial boards and professional advisory boards related to molecular immunology, autoimmunity, and immunotherapy. Dr. Nepom has published over 350 scientific papers in the areas of immunology, genetics, and autoimmunity.

Dr. Nepom received his A.B. magna cum laude (1972) from Harvard University and Ph.D. in Biochemistry (1977) and M.D. (1978) from the University of Washington (UW).


John Latham, Ph.D.

John A. Latham, Ph.D.

Dr. John Latham has over 30 years’ experience in senior scientific management roles.  Dr. Latham most recently served as Chief Scientific Officer and co-Founder at Alder BioPharmaceuticals.  Prior to this, he served as a director, senior director, and Vice President of Gene Function and Target Validation for Celltech Group plc. Dr. Latham joined Darwin Molecular Corporation as a founding director and joined Gilead Sciences, Inc. as one of its earliest scientists.

Dr. Latham holds a Ph.D. in Biochemistry from Massachusetts Institute of Technology and a B.S. in Chemistry from Colorado State University.


Lee E. Babiss, Ph.D.

Lee E. Babiss, Ph.D.

Dr. Lee Babiss has over 35 years of experience establishing and leading research and development programs and companies.  Dr. Babiss has served as CEO and Co-Founder of Gotham Therapeutics, CSO and SVP of PPD, president of pharma research at Roche, and VP of human genetics and personalized health care at GlaxoWellcome in addition to his most recent tenure as President and Board Chairman of X-Chem and CEO of X-Rx. Dr. Babiss has received numerous fellowship awards and grants and serves on several scientific advisory committees and boards. Dr. Babiss has published over 60 peer-reviewed scientific papers.

Dr. Babiss received his doctorate in Microbiology from Columbia University and completed his postdoctoral fellowship at the Rockefeller University, where he served as an assistant and associate professor.


George L. McLendon, Ph.D.

George L. McLendon, Ph.D.

Dr. George McLendon has over four decades experience in academics, research science, company building and executive leadership.  Dr. McLendon is currently the CEO of ML Bio Solutions, Inc. Previously, he served as the Vice President of Therapeutic Research and Development at Atrium Health. Prior to this role, he was Howard Hughes Provost and Professor of Chemistry at Rice University. Before joining Rice, Dr. McLendon was Dean of Arts and Sciences, Professor of Chemistry and Biochemistry at Duke University and faculty member of the Cancer Center at Duke University Medical School. Dr. McLendon was also the chair of the Department of Chemistry at Princeton University and Professor of Chemistry and Biochemistry at the University of Rochester.  Dr. McLendon’s work has contributed to the establishment of several companies including Tetralogic, Steamtrax and Labcyte.  He is a founding co-director of TMCx, the largest accelerator for biomedical startups, and serves on advisory and governing boards for several early-stage life science companies.

Dr. McLendon earned a PhD degree in Chemistry from Texas A&M University.


Homer L. Pearce, Ph.D.

Homer L. Pearce, Ph.D.

Dr. Homer Pearce served for 27-years at Eli Lilly devoting his research to cancer drug discovery and clinical development.  Dr. Pearce held several positions of increasing responsibility at Lilly, all of which were directed at the discovery and development of new drugs to treat cancer. He served as Vice President of Cancer Research and Clinical Investigation and became a Distinguished Research Fellow, Cancer Research. During this time Lilly’s cancer drug discovery group introduced 25 investigational drugs into clinical trials and 3 new drugs were approved for the treatment of cancer by worldwide regulatory agencies including Gemzar and ALIMTA. Dr. Pearce has since retired from Lilly, and has served in several board, consulting and advisory roles in the academic, government and biopharmaceutical communities.

Homer Pearce received a BS degree in chemistry from Texas A&M University in 1974 and was awarded a PhD in organic chemistry from Harvard University in 1979.